Compare Stocks: RNAZ, SPRB, LUCD, and CLLS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLLS Cellectis	$0.98 +0.7%	$2.14	$0.88 ▼ $5.45	$97.18M	3	102,929 shs	129,353 shs
LUCD Lucid Diagnostics	$0.33 -1.7%	$0.78	$0.30 ▼ $1.63	$67.76M	1.12	2.42 million shs	30.91 million shs
RNAZ TransCode Therapeutics	$1.72 +3.6%	$1.99	$1.52 ▼ $13.96	$28.10M	1.25	32,451 shs	27,964 shs
SPRB Spruce Biosciences	$46.00 +7.7%	$50.94	$38.06 ▼ $140.45	$122.81M	3.25	72,572 shs	126,491 shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLLS Cellectis	+0.67%	-11.76%	-37.50%	-65.67%	-72.84%
LUCD Lucid Diagnostics	-1.71%	-36.99%	-63.29%	-63.89%	-73.14%
RNAZ TransCode Therapeutics	+3.61%	-4.44%	-2.82%	-70.99%	-86.16%
SPRB Spruce Biosciences	+7.65%	+10.92%	-7.98%	+6.78%	-67.27%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLLS Cellectis	$0.98 +0.7%	$2.14	$0.88 ▼ $5.45	$97.18M	3	102,929 shs	129,353 shs
LUCD Lucid Diagnostics	$0.33 -1.7%	$0.78	$0.30 ▼ $1.63	$67.76M	1.12	2.42 million shs	30.91 million shs
RNAZ TransCode Therapeutics	$1.72 +3.6%	$1.99	$1.52 ▼ $13.96	$28.10M	1.25	32,451 shs	27,964 shs
SPRB Spruce Biosciences	$46.00 +7.7%	$50.94	$38.06 ▼ $140.45	$122.81M	3.25	72,572 shs	126,491 shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLLS Cellectis	+0.67%	-11.76%	-37.50%	-65.67%	-72.84%
LUCD Lucid Diagnostics	-1.71%	-36.99%	-63.29%	-63.89%	-73.14%
RNAZ TransCode Therapeutics	+3.61%	-4.44%	-2.82%	-70.99%	-86.16%
SPRB Spruce Biosciences	+7.65%	+10.92%	-7.98%	+6.78%	-67.27%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLLS Cellectis	2.29	Hold	$5.46	460.00% Upside
LUCD Lucid Diagnostics	2.60	Moderate Buy	$4.19	1,177.85% Upside
RNAZ TransCode Therapeutics	1.00	Sell	N/A	N/A
SPRB Spruce Biosciences	2.83	Moderate Buy	$158.33	244.20% Upside

Current Analyst Ratings Breakdown

Latest RNAZ, SPRB, LUCD, and CLLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	RNAZ TransCode Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/6/2026	SPRB Spruce Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/2/2026	CLLS Cellectis	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/1/2026	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/24/2026	SPRB Spruce Biosciences	Citizens Jmp Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform	$144.00
9/18/2026	SPRB Spruce Biosciences	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
9/17/2026	SPRB Spruce Biosciences	Lake Street Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$149.00
9/16/2026	CLLS Cellectis	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/16/2026	SPRB Spruce Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/16/2026	CLLS Cellectis	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Overweight ➝ Underweight	$9.00 ➝ $1.30
9/15/2026	CLLS Cellectis	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$10.00 ➝ $8.00

(Data available from 10/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLLS Cellectis	$79.59M	1.23	N/A	N/A	$0.76 per share	1.28
LUCD Lucid Diagnostics	$4.71M	14.14	N/A	N/A	($0.31) per share	-1.06
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	$11.27 per share	N/A
SPRB Spruce Biosciences	$4.91M	26.89	N/A	N/A	$39.72 per share	1.16

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLLS Cellectis	-$67.59M	-$0.65	N/A	N/A	N/A	-102.34%	-94.19%	-21.34%	11/13/2026 (Estimated)
LUCD Lucid Diagnostics	-$58.01M	-$0.47	N/A	N/A	N/A	-959.76%	N/A	-119.57%	11/11/2026 (Estimated)
RNAZ TransCode Therapeutics	-$34.66M	-$52.37	N/A	N/A	N/A	N/A	-875.35%	-37.46%	11/18/2026 (Estimated)
SPRB Spruce Biosciences	-$38.97M	-$39.78	N/A	N/A	N/A	N/A	-123.53%	-90.35%	11/9/2026 (Estimated)

Latest RNAZ, SPRB, LUCD, and CLLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/13/2026	Q3 2026	CLLS Cellectis	-$0.18	N/A	N/A	N/A	$15.61 million	N/A
11/11/2026	Q3 2026	LUCD Lucid Diagnostics	-$0.04	N/A	N/A	N/A	$1.64 million	N/A
11/9/2026	Q3 2026	SPRB Spruce Biosciences	-$5.6756	N/A	N/A	N/A	$50.00 million	N/A
8/14/2026	Q2 2026	RNAZ TransCode Therapeutics	N/A	-$7.17	N/A	-$7.17	N/A	N/A
8/12/2026	Q2 2026	LUCD Lucid Diagnostics	-$0.0567	-$0.06	-$0.0033	-$0.08	$1.43 million	$1.47 million
8/12/2026	Q2 2026	SPRB Spruce Biosciences	-$5.79	-$6.68	-$0.89	-$6.68	N/A	N/A
8/7/2026	H1 2026	CLLS Cellectis	-$0.2630	-$0.22	+$0.0430	-$0.22	$11.05 million	$6.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLLS Cellectis	1.61	1.37	1.37
LUCD Lucid Diagnostics	N/A	1.33	1.31
RNAZ TransCode Therapeutics	N/A	1.97	1.97
SPRB Spruce Biosciences	0.05	9.23	9.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLLS Cellectis	63.90%
LUCD Lucid Diagnostics	74.01%
RNAZ TransCode Therapeutics	N/A
SPRB Spruce Biosciences	91.71%

Insider Ownership

Company	Insider Ownership
CLLS Cellectis	16.41%
LUCD Lucid Diagnostics	6.90%
RNAZ TransCode Therapeutics	0.10%
SPRB Spruce Biosciences	4.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLLS Cellectis	229	100.34 million	83.87 million	Optionable
LUCD Lucid Diagnostics	82	203.24 million	189.22 million	No Data
RNAZ TransCode Therapeutics	12	16.93 million	16.91 million	Not Optionable
SPRB Spruce Biosciences	8	2.87 million	2.75 million	Optionable

RNAZ, SPRB, LUCD, and CLLS Headlines

Recent News About These Companies

Spruce Biosciences, Inc. (SPRB) - What Are Investment Firms Thinking About This Stock?

October 18, 2026 | americanbankingnews.com

Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference

October 15, 2026 | finance.yahoo.com

Spruce Biosciences, Inc. (NASDAQ:SPRB) Stock Rated "Moderate Buy" by Wall Street Analysts

October 13, 2026 | marketbeat.com

Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting

October 8, 2026 | financialpost.comF

Analysts Are Bullish on These Healthcare Stocks: Spruce Biosciences (SPRB), Arcus Biosciences (RCUS)

October 3, 2026 | theglobeandmail.com

Citizens Jmp Reaffirms "Market Outperform" Rating for Spruce Biosciences (NASDAQ:SPRB)

September 24, 2026 | marketbeat.com

Spruce Biosciences (SPRB) Reiterated at Market Outperform by Citizens on TA-ERT Therapy Lead

September 24, 2026 | streetinsider.com

Lake Street initiates coverage of Spruce Biosciences at buy

September 18, 2026 | msn.com

Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026 | businesswire.com

Oppenheimer Sticks to Its Buy Rating for Spruce Biosciences (SPRB)

August 28, 2026 | theglobeandmail.com

Spruce Biosciences stock gains after analyst backs regulatory progress

August 27, 2026 | finance.yahoo.com

Spruce Biosciences Announces Launch of MPS3BStudy.com

August 26, 2026 | finance.yahoo.com

Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026

August 24, 2026 | finance.yahoo.com

Spruce Biosciences Inc.

August 16, 2026 | marketwatch.com

Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

August 12, 2026 | aol.comA

Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences

August 12, 2026 | finance.yahoo.com

Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development

August 3, 2026 | finance.yahoo.com

Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer

July 27, 2026 | finance.yahoo.com

Spruce Biosciences Names Adrian Quartel Chief Medical Officer

July 27, 2026 | tipranks.com

Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

July 8, 2026 | finance.yahoo.com

Spruce Biosciences Possibly First In-MPS IIIB Class Enzyme Replacement Therapy

July 8, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ, SPRB, LUCD, and CLLS Company Descriptions

Cellectis NASDAQ:CLLS

$0.98 +0.01 (+0.67%)

Closing price 10/22/2026 04:00 PM Eastern

Extended Trading

$0.98 0.00 (0.00%)

As of 10/22/2026 07:54 PM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Lucid Diagnostics NASDAQ:LUCD

$0.33 -0.01 (-1.71%)

Closing price 10/22/2026 04:00 PM Eastern

Extended Trading

$0.51 +0.18 (+55.32%)

As of 10/22/2026 07:59 PM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

TransCode Therapeutics NASDAQ:RNAZ

$1.72 +0.06 (+3.61%)

Closing price 10/22/2026 04:00 PM Eastern

Extended Trading

$1.71 -0.01 (-0.58%)

As of 10/22/2026 07:30 PM Eastern

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

Spruce Biosciences NASDAQ:SPRB

$46.00 +3.27 (+7.65%)

Closing price 10/22/2026 04:00 PM Eastern

Extended Trading

$46.16 +0.16 (+0.36%)

As of 10/22/2026 07:30 PM Eastern

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNAZ, SPRB, LUCD, and CLLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNAZ, SPRB, LUCD, and CLLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNAZ, SPRB, LUCD, and CLLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ, SPRB, LUCD, and CLLS Company Descriptions

Cellectis NASDAQ:CLLS

Lucid Diagnostics NASDAQ:LUCD

TransCode Therapeutics NASDAQ:RNAZ

Spruce Biosciences NASDAQ:SPRB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNAZ, SPRB, LUCD, and CLLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNAZ, SPRB, LUCD, and CLLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNAZ, SPRB, LUCD, and CLLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ, SPRB, LUCD, and CLLS Company Descriptions

Cellectis NASDAQ:CLLS

Lucid Diagnostics NASDAQ:LUCD

TransCode Therapeutics NASDAQ:RNAZ

Spruce Biosciences NASDAQ:SPRB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools